This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Acrotech Biopharma, LLC
Acrotech Biopharma, LLC, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in the development and commercialisation of innovative therapies. Founded in 2018, Acrotech has quickly established itself as a leader in oncology and rare disease treatments, focusing on delivering high-quality, patient-centric solutions. With a robust portfolio of unique products, Acrotech Biopharma is dedicated to addressing unmet medical needs through advanced drug formulations and strategic partnerships. The company’s commitment to research and development has led to significant milestones, enhancing its market position and reputation for excellence. As a trusted name in biopharma, Acrotech continues to make strides in improving patient outcomes and advancing healthcare solutions globally.
DitchCarbon Score
How does Acrotech Biopharma, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acrotech Biopharma, LLC's score of 43 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Acrotech Biopharma, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Aurobindo Pharma Limited, which means that any emissions data or climate commitments may be inherited from this parent organisation. As of now, Acrotech Biopharma has not established specific reduction targets or climate pledges. The absence of documented reduction initiatives suggests that the company may still be in the early stages of developing its climate strategy. Given its affiliation with Aurobindo Pharma Limited, any relevant emissions data or sustainability initiatives would likely be aligned with the parent company's commitments. However, without specific figures or targets from Acrotech Biopharma, it is challenging to provide a detailed overview of its carbon footprint or climate commitments. In summary, Acrotech Biopharma, LLC is currently reliant on its parent company for emissions data and climate initiatives, with no specific targets or achievements reported at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 409,572,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 523,611,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Acrotech Biopharma, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
